214 related articles for article (PubMed ID: 30761563)
1. Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis.
Santiago P; Schwartz I; Tamariz L; Levy C
Aliment Pharmacol Ther; 2019 Apr; 49(7):830-839. PubMed ID: 30761563
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
Abdollahi M; Ekrami NK; Ghojazadeh M; Boezen HM; Somi M; Alizadeh BZ
World J Gastroenterol; 2020 Oct; 26(38):5896-5910. PubMed ID: 33132643
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis.
Efe C; Hagström H; Ytting H; Bhanji RA; Müller NF; Wang Q; Purnak T; Muratori L; Werner M; Marschall HU; Muratori P; Gunşar F; Klintman D; Parés A; Heurgué-Berlot A; Schiano TD; Cengiz M; May-Sien Tana M; Ma X; Montano-Loza AJ; Berg T; Verma S; Larsen FS; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1950-1956.e1. PubMed ID: 28603052
[TBL] [Abstract][Full Text] [Related]
4. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis.
Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Tushuizen ME; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Baven Pronk MAMC; Beuers U; van der Meer AJ; Gerven NMFV; Sijtsma MGM; van Eijck BC; van IJzendoorn MC; van Herwaarden M; van den Brand FF; Korkmaz KS; van den Berg AP; Guichelaar MMJ; Levens AD; van Hoek B; Drenth JPH;
J Hepatol; 2024 Apr; 80(4):576-585. PubMed ID: 38101756
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy.
Roberts SK; Lim R; Strasser S; Nicoll A; Gazzola A; Mitchell J; Siow W; Khoo T; Hamarneh Z; Weltman M; Gow P; Janko N; Tse E; Mishra G; Cheng EH; Levy M; Cheng W; Sood S; Skoien R; Mitchell J; Zekry A; George J; MacQuillan G; Wigg A; Stuart K; Sievert W; McCaughan G;
Clin Gastroenterol Hepatol; 2018 Feb; 16(2):268-277. PubMed ID: 29050991
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis.
Efe C; Taii HA; Ytting H; Aehling N; Bhanji RA; Hagström H; Purnak T; Muratori L; Werner M; Muratori P; Klintman D; Schiano TD; Montano-Loza AJ; Berg T; Larsen FS; Alkhouri N; Ozaslan E; Heneghan MA; Yoshida EM; Wahlin S
Dig Dis Sci; 2018 May; 63(5):1348-1354. PubMed ID: 29569003
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
Hennes EM; Oo YH; Schramm C; Denzer U; Buggisch P; Wiegard C; Kanzler S; Schuchmann M; Boecher W; Galle PR; Adams DH; Lohse AW
Am J Gastroenterol; 2008 Dec; 103(12):3063-70. PubMed ID: 18853972
[TBL] [Abstract][Full Text] [Related]
8. Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis.
Yu ZJ; Zhang LL; Huang TT; Zhu JS; He ZB
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):873-877. PubMed ID: 31150366
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.
Zachou K; Gatselis N; Papadamou G; Rigopoulou EI; Dalekos GN
J Hepatol; 2011 Sep; 55(3):636-646. PubMed ID: 21238519
[TBL] [Abstract][Full Text] [Related]
11. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
[TBL] [Abstract][Full Text] [Related]
12. Second-line Agents in Pediatric Patients With Autoimmune Hepatitis: A Systematic Review and Meta-analysis.
Zizzo AN; Valentino PL; Shah PS; Kamath BM
J Pediatr Gastroenterol Nutr; 2017 Jul; 65(1):6-15. PubMed ID: 28644343
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil for autoimmune hepatitis: a single practice experience.
Wolf DC; Bojito L; Facciuto M; Lebovics E
Dig Dis Sci; 2009 Nov; 54(11):2519-22. PubMed ID: 19082888
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of patients with difficult-to-treat autoimmune hepatitis receiving mycophenolate mofetil.
Liberal R; Gaspar R; Lopes S; Macedo G
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101487. PubMed ID: 32651078
[TBL] [Abstract][Full Text] [Related]
16. First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients.
Dalekos GN; Arvaniti P; Gatselis NK; Samakidou A; Gabeta S; Rigopoulou E; Koukoulis GK; Zachou K
Front Immunol; 2021; 12():798602. PubMed ID: 35087524
[TBL] [Abstract][Full Text] [Related]
17. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial.
Snijders RJALM; Stoelinga AEC; Gevers TJG; Pape S; Biewenga M; Verdonk RC; de Jonge HJM; Vrolijk JM; Bakker SF; Vanwolleghem T; de Boer YS; Pronk MAMCB; Beuers UHW; van der Meer AJ; van Gerven NMF; Sijtsma MGM; Verwer BJ; Gisbertz IAM; Bartelink M; van den Brand FF; Sebib Korkmaz K; van den Berg AP; Guichelaar MMJ; Soufidi K; Levens AD; van Hoek B; Drenth JPH;
Trials; 2022 Dec; 23(1):1012. PubMed ID: 36514163
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine.
Richardson PD; James PD; Ryder SD
J Hepatol; 2000 Sep; 33(3):371-5. PubMed ID: 11019991
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.
Aw MM; Dhawan A; Samyn M; Bargiota A; Mieli-Vergani G
J Hepatol; 2009 Jul; 51(1):156-60. PubMed ID: 19446911
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy.
Fallatah HI; Akbar HO
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):517-22. PubMed ID: 21780898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
